Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Ming-Ming Zhou
Icahn School of Medicine at Mount Sinai, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Parkside Scientific Inc
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Ming-Ming Zhou (the Principal Investigator in this study) is the founder, Chief Scientist, and equity owner of Parkside Scientific Inc.. Parkside is a biotechnology company that focuses on developing small molecule inhibitor drugs for the treatment of cancers and other diseases that target a major gene transcriptional regulator, BRD4.
Dr. Zhou is also an inventor on patents licensed by the Icahn School of Medicine at Mount Sinai to Parkside Scientific. The outcomes of this research could therefore provide financial benefits to both Dr. Zhou and the Icahn School of Medicine at Mount Sinai.
Transcriptional Mechanism of BRD4 in Solid Tumor
PROJECT NARRATIVE Solid tumors are much more challenging for therapeutic treatment than hematopoietic cancers. The complex nature of persistent oncogene transcription in solid tumors defies full mechanistic investigation with conventional approaches. The proposed study will develop novel research tools to gain mechanistic insights into epigenetic control of oncogene transcriptional activation and explore novel cancer therapy strategy to combat some most aggressive forms of cancer that lack effective treatments.
Filed on July 01, 2019.
Tell us what you know about Ming-Ming Zhou's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.